Celldex Releases Data, Biostar Announces Q3 Results Date: Healthcare Business Review

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Sanofi-aventis (NYSE:SNY) and Regeneron Pharmaceuticals (NASDAQ:REGN) reported in a press release Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion and also recommended that marketing authorization for Zaltrap (ziv-aflibercept) Injection be granted for Intravenous Infusion in combination with irinotecan/5-fluorouracil/folinic acid chemotherapy in adults suffering from metastatic colorectal cancer which is resistant to, or has progressed after an oxaliplatin-containing regimen.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Celldex Therapeutics (NASDAQ: CLDX) reported in a release on Thursday the presentation of three-year survival data from the Phase 2 rindopepimut clinical program in EGFRvIII-positive glioblastoma, a more aggressive form of glioblastoma typically associated with reduced long-term survival when compared to the entire glioblastoma population. Further, across three Phase 2 studies of rindopepimut, the survival data remains consistent and implies a substantial and continuing survival benefit, when compared to independent control data sets at the median and also at three years.

In a press release from China, Biostar Pharmaceuticals (NASDAQ:BSPM), said that it will issue its financial results for the third quarter on Monday, before the open of the market. The firm is based in China, and manufactures and markets  pharmaceutical and health supplement products for a varied number of diseases and conditions.

Don’t Miss: Here’s Another Hard Knock for GlaxoSmithKline.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business